ForSight Robotics demonstrates fully robotic-assisted cataract surgery within the standard clinical workflow of the world's most commonly performed surgical procedure. August 6, 2026 Latest clinical experience, bringing the Company's first-in-human study to a total of 26 patients, demonstrates 100% robotic completion of all procedures, standard cataract anesthesia protocols, same-day discharge, and successful integration into routine clinical practice. CAESAREA, Israel-(BUSINESS WIRE)-ForSight Robotics, a global pioneer in robotic eye surgery, today announced a significant milestone in the clinical evolution of ophthalmic robotics, demonstrating that fully robotic-assisted cataract surgery can be successfully integrated into the standard clinical workflow of the world's most commonly performed surgical procedure. Building on the Company's historic first-in-human achievement announced earlier this year, ForSight Robotics has successfully completed an additional 14 fully robotic-assisted cataract surgeries using the JASPER(TM) Robotic Surgical Platform, bringing its total first-in-human clinical experience to 26 patients. Across all 26 procedures, 100% were successfully completed robotically without conversion to manual surgery. All patients underwent surgery using standard cataract anesthesia protocols, receiving either topical anesthesia alone or mild sedation, consistent with routine clinical practice, and all patients were discharged the same day, consistent with standard outpatient cataract surgery. "Cataract surgery is performed more than 30 million times each year worldwide, making it the world's most commonly performed surgical procedure," said Joseph Nathan, MD, MSc, co-founder and Chief Executive Officer of ForSight Robotics. "Our first clinical milestone established that fully robotic-assisted cataract surgery was possible. This latest clinical experience demonstrates something even more important: that robotic cataract surgery can integrate naturally into the way cataract surgery is performed every day. This represents a defining milestone, not only for ForSight Robotics, but for the future of ophthalmic surgery." The procedures were performed as part of the Company's ongoing first-in-human clinical study by Dr. Alexey Rapoport, with Dr. Robert T. Ang, Senior Consultant and Head of the Cornea and Refractive Surgery Services at the Asian Eye Institute, as Principal Investigator of the study. "One of the most encouraging aspects of this clinical experience has been how seamlessly the robotic platform fits into routine cataract surgery," said Dr. Ang. "Patients underwent surgery using the same anesthesia approaches we use every day, either topical anesthesia alone or mild sedation, and were discharged the same day following standard postoperative care. The robotic platform complemented, rather than disrupted, the normal clinical workflow while providing exceptional precision, stability, and control." JASPER(TM) is the world's first robotic surgical platform designed to perform the complete cataract procedure through intuitive surgeon-controlled telemanipulation. The platform combines bimanual robotic manipulation, high-definition three-dimensional visualization, real-time eye tracking, motion scaling, tremor elimination, and advanced computer vision technologies to enhance surgical precision while maintaining the surgeon's control throughout every step of the procedure. The expanded first-in-human clinical experience represents another important milestone as ForSight Robotics advances toward clinical studies and regulatory submissions. By demonstrating compatibility with the standard workflow of cataract surgery, including routine anesthesia practices, same-day outpatient care, and consistent robotic execution, the Company continues to build evidence supporting the adoption of robotic technology in ophthalmology. "Our vision extends beyond robotics," added Nathan. "We believe robotic platforms will become the foundation for the next generation of intelligent surgery. By integrating seamlessly into today's clinical practice, we are building the platform that will enable the future evolution of AI-enabled surgical capabilities in the operating room." About ForSight Robotics ForSight Robotics is developing the robotic foundation for the next generation of intelligent surgery and the future physical agent of AI in the operating room. The Israel-based company is pioneering world-class technology to democratize quality surgical eye care through its flagship JASPER(TM)(Joint Aligned System for Precise Eye Robotics) Robotic Surgical Platform. By bringing robotics to the world's most commonly performed surgical procedure, ForSight Robotics aims to improve surgical outcomes today while establishing the foundation for future AI-enabled surgical capabilities. Backed by globally recognized venture capital firms and industry leaders, ForSight Robotics is redefining ophthalmic surgery and bringing hope to millions of patients worldwide. To learn more, visit forsightrobotics.com and follow on LinkedIn. The JASPER(TM) Robotic Surgical Platform is under design and development and has not yet been approved for commercial use. Contacts. For media inquiries, contact: Lisa Sferrazza-Cohen Director, Communication & PR [email protected]

ForSight Robotics has completed the world's first fully robot-assisted cataract surgery in a human patient using its JASPER Platform. The procedure was performed by Dr Alexey Rapoport at the Asian Eye Institute in Manila, marking the first time a cataract surgery has been completed entirely robotically without general anaesthesia. Unlike previous partial robotic procedures, the JASPER Platform assists surgeons through every step of cataract surgery, providing advanced imaging, precision and motion scaling whilst reducing surgeon fatigue. The system is designed to address a global shortage of trained surgeons and improve access to care. An estimated 600 million people worldwide need cataract surgery, yet only 30 million procedures are performed annually. Following its Series B funding in 2025, ForSight Robotics will advance toward clinical validation and regulatory submissions.